Antibody Mal-PEG4-VC-PAB-MMAF Conjugation Kit, 3 vial

This Mal-PEG4-VC-PAB-MMAF Conjugation Kit is designed to conjugate 1 mg of antibody with the chemotherapeutic drug, MMAF via standard malemide/thiol chemistry. The linker structure (shown below) is also composed of a cleavable val-cit dipeptide, which enhances drug molecule release to the cell. The Monomethyl auristatin F (MMAF) is an antitubulin agent that inhibits cell division by blocking the polymerization of tubulin. It is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, monomethyl auristatin E (MMAE). Because of MMAF is highly toxic, it cannot be used as a drug itself. MMAF induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism. This product is used for research only.

Product Details